As of close of business last night, TC BioPharm (Holdings) plc ADR’s stock clocked out at $1.62, down -3.57% from its previous closing price of $1.68. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 800723 shares were traded.
Ratios:
To gain a deeper understanding of TCBP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.09 and its Current Ratio is at 1.09. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 0.83.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TCBP now has a Market Capitalization of 3.98M and an Enterprise Value of 4.50M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.33 while its Price-to-Book (P/B) ratio in mrq is 126.37. Its current Enterprise Value per Revenue stands at 1.58 whereas that against EBITDA is -3.78.
Stock Price History:
Over the past 52 weeks, TCBP has reached a high of $82.60, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 1.5187, while the 200-Day Moving Average is calculated to be 59.4486.
Shares Statistics:
It appears that TCBP traded 3.31M shares on average per day over the past three months and 15.34M shares per day over the past ten days. Shares short for TCBP as of Feb 29, 2024 were 196.99k with a Short Ratio of 0.06, compared to 98.01k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.12% and a Short% of Float of 8.12%.
Earnings Estimates
As of right now, 0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$228.4 and -$228.4 for the fiscal current year, implying an average EPS of -$228.4. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
